证券代码：002166 证券简称：莱茵生物 公告编号：2025-079 桂林莱茵生物科技股份有限公司 关于股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到大股 东秦本军先生的通知，获悉秦本军先生将其所持有的部分公司股份办理了解除质 押及再质押手续，现将具体情况公告如下： 注：表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致（下同）。 | 二、股东本次股份质押的基本情况 | | --- | 桂林莱茵生物科技股份有限公司 | | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | 合计占 | 占公司 | 已 质 押 股 | | 未质押股 | | | 股东 | 持股数量 | 持股比 | 前质押股 | 后质押股 | 其所持 | 总股本 | 份 限 售 和 | ...

Group 1 - The company announced that major shareholder Qin Benjun has notified the board about the release and re-pledging of part of his shares [1] - As of the announcement date, Qin Benjun has pledged a total of approximately 173 million shares, accounting for 23.29% of the company's total share capital [1] Group 2 - The automotive market is experiencing a surge in sales, with BMW's base price significantly reduced from the original guidance of 349,900 yuan to 225,000 yuan, alongside various subsidies for purchase taxes from multiple car manufacturers [1]

Group 1 - The core viewpoint of the news is that 莱茵生物 (Laiyin Bio) has experienced a stock price increase of 2.01% this year, despite a recent decline of 8.59% over the last five trading days [2] - As of January 5, the stock price is reported at 8.62 yuan per share, with a total market capitalization of 6.393 billion yuan [1] - The company primarily engages in the production and operation of natural health products, focusing on the extraction of functional plant components, with 98.05% of its revenue coming from plant extraction products [2] Group 2 - For the period from January to September 2025, 莱茵生物 achieved a revenue of 1.272 billion yuan, reflecting a year-on-year growth of 8.73%, while the net profit attributable to shareholders decreased by 30.73% to 70.3953 million yuan [2] - The company has distributed a total of 431 million yuan in dividends since its A-share listing, with 294 million yuan distributed over the past three years [3] - The number of shareholders as of September 30 is reported at 46,000, a decrease of 1.66% from the previous period, while the average circulating shares per person increased by 31.16% to 16,011 shares [2]

Core Viewpoint - The control of Rhein Biotech (002166.SZ), known as the "first stock of plant extraction," will be transferred to Guangzhou Defu Nutrition, led by the well-known investment institution Defu Capital, alongside a strategic acquisition of 80% of Beijing Jinkangpu, a company specializing in food nutrition fortifiers [2][3]. Group 1: Company Overview - Rhein Biotech is a leading player in the global plant extraction industry, with over 20 years of experience in natural sweeteners, holding a significant market share in stevia and monk fruit extracts [3]. - The company has recently achieved a major milestone with its synthetic biology technology, which is expected to generate over 1 billion yuan in annual output once its first domestic production line reaches full capacity [3]. Group 2: Financial Performance - Despite revenue growth, Rhein Biotech's net profit attributable to shareholders decreased by 30.73% year-on-year in the third quarter of 2025, highlighting the industry's challenges of intensified competition and price pressure [3]. Group 3: Strategic Moves - The acquisition by Defu Capital is not merely a financial investment but aims to vertically integrate the industry chain by acquiring control and injecting assets to fill Rhein Biotech's downstream gaps [4]. - The injected asset, Beijing Jinkangpu, is a leader in the food nutrition fortifier sector, providing a strategic intent to create an industry closed loop, allowing Rhein Biotech's upstream natural extracts to supply high-value nutrition fortifiers and end products [4]. Group 4: Future Outlook - Post-acquisition, Rhein Biotech's development path is clear, with short-term synergies expected to enhance profitability and risk resilience [5]. - In the medium to long term, the company will transition from a single plant extract supplier to a comprehensive platform covering "natural raw materials—core ingredients—end formulations," expanding into broader health and nutrition sectors [5]. - The success of this integration will determine whether Rhein Biotech can navigate through cycles and secure a more significant position in the global health industry [5].

Core Viewpoint - The increasing health awareness among the public and the deepening "sugar reduction" consciousness have made sugar-free/low-sugar food and beverages mainstream choices, with steviol glycosides emerging as a preferred alternative to sucrose and artificial sweeteners due to their natural, low-calorie, and blood sugar-neutral characteristics. The "Healthy China" strategy and related policies are driving food and beverage companies to adopt natural sweeteners, leading to a projected market size of 1.037 billion yuan for the steviol glycoside industry in China by 2024, representing a year-on-year growth of 10.2% [1][10]. Industry Overview - Steviol glycosides, derived from the Stevia plant, are natural sweeteners with a sweetness level 200-300 times that of sucrose and only 1/300 of its calories, making them suitable substitutes for sugar [2][4]. - The industry has evolved through five stages: introduction, initial industrialization, rapid expansion, adjustment and integration, and high-end upgrading, transitioning from low-end raw material supply to a comprehensive industry chain and high-end product leadership [4][5]. Market Policies - Recent policies emphasize food safety and quality control, including the "14th Five-Year Plan for National Health" and various regulations aimed at optimizing food additive standards, which encourage the use of steviol glycosides and promote a shift towards a more standardized, green, and high-quality industry [6][9]. Industry Chain - The steviol glycoside industry chain includes upstream activities such as the cultivation and harvesting of Stevia, midstream processes like extraction and purification, and downstream applications in food, beverages, health products, pharmaceuticals, and daily chemicals [6][8]. Current Market Demand - The food and beverage sectors are the primary consumers of steviol glycosides, with sugar-free beverages, baked goods, dairy products, and seasonings increasingly incorporating these sweeteners. By 2024, these sectors are expected to account for over 60% of the market [8][10]. Competitive Landscape - The market concentration of the steviol glycoside industry has increased, with leading companies such as Guilin Liyang Biotechnology Co., Ltd. and Chenguang Biotech Group Co., Ltd. dominating the market through technological innovation and comprehensive industry chain strategies [10][11]. Company Analysis - Guilin Liyang Biotechnology Co., Ltd. reported a total revenue of 837 million yuan and a gross profit of 197 million yuan in the first half of 2025, with a gross margin of 23.57% [11]. - Chenguang Biotech Group Co., Ltd. achieved a revenue of 3.658 billion yuan and a gross profit of 507 million yuan in the same period, with a gross margin of 13.86% [11]. Future Development Trends - The industry is expected to focus on high-quality rare components like RebA/RebD/RebM, with a shift from homogeneous price competition to high-end product value competition. There will be a transition from single steviol glycosides to composite products that combine steviol glycosides with other functional ingredients, catering to specific dietary needs [12][13].

具体来看，今日上榜的营业部中，共有2家机构专用席位现身，即卖三、卖五，合计买入金额271.37万元，卖出金额2879.60万元，合计净卖出 2608.23万元。 （原标题：莱茵生物龙虎榜数据（12月25日）） 莱茵生物今日下跌1.46%，全天换手率11.57%，成交额8.29亿元，振幅15.48%。龙虎榜数据显示，机构净卖出2608.23万元，营业部席位合计净卖 出2610.63万元。 深交所公开信息显示，当日该股因日振幅值达15.48%上榜，机构专用席位净卖出2608.23万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交1.44亿元，其中，买入成交额为4582.41万元，卖出成交额为9801.26万元，合计净 卖出5218.85万元。 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 招商证券股份有限公司桂林中山北路证券营业部 | 1207.27 | 287.43 | | 买二 | 国海证券股份有限公司桂林分公司 | 822.92 | 274.05 | | 买三 | 广发证券股份有限公司西安南广济 ...

资金流向方面，主力资金净流出4863.30万元，特大单买入1389.02万元，占比5.57%，卖出7028.65万 元，占比28.17%；大单买入5585.97万元，占比22.39%，卖出4809.64万元，占比19.28%。 莱茵生物今年以来股价涨27.10%，近5个交易日涨7.58%，近20日涨12.48%，近60日涨18.16%。 12月25日，莱茵生物（维权）盘中下跌2.09%，截至09:35，报9.37元/股，成交2.49亿元，换手率 3.42%，总市值69.49亿元。 资料显示，桂林莱茵生物科技股份有限公司位于广西壮族自治区桂林市临桂区人民南路19号，成立日期 2000年11月28日，上市日期2007年9月13日，公司主营业务涉及主要从事天然健康产品的生产经营业 务，持续专注植物功能性成分提取领域。主营业务收入构成为：植物提取产品98.05%，其他业务产品 1.95%。 莱茵生物所属申万行业为：基础化工-化学制品-食品及饲料添加剂。所属概念板块包括：专精特新、啤 酒、融资融券、小盘、代糖概念等。 截至9月30日，莱茵生物股东户数4.60万，较上期减少1.66%；人均流通股16011股，较上期增加 ...

Core Viewpoint - The transfer of control and asset injection into Rhine Biotech is seen as a crucial move to address the company's operational challenges and enhance its market position following the departure of its founder due to regulatory penalties [1][2]. Group 1: Control Change and Asset Injection - Rhine Biotech's controlling shareholder, Qin Benjun, plans to transfer 8.09% of shares to Guangzhou Defu Nutrition for 645.6 million yuan, relinquishing 25.5% of voting rights [1][3]. - After the transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as joint actual controllers [1][3]. - The company will also acquire an 80% stake in Beijing Jinkangpu Food Technology through a share issuance, marking a significant asset injection [1][5]. Group 2: Financial Performance and Challenges - For the first three quarters of 2025, Rhine Biotech reported revenues of 1.272 billion yuan, an increase of 8.73%, but a net profit of 70.4 million yuan, down 30.73% year-on-year [1][8]. - Qin Benjun faces significant financial pressure, with over 65% of his shares pledged and a financing balance of 207 million yuan due within six months [1][8]. Group 3: New Business Direction - The acquisition of Beijing Jinkangpu, a leader in food nutrition fortifiers, allows Rhine Biotech to enter the nutrition health sector, expanding its business model [7][10]. - Beijing Jinkangpu's revenue for 2023 to the first nine months of 2025 was 370 million yuan, 432 million yuan, and 338 million yuan, respectively [9]. - The transaction is expected to create a closed-loop industry chain from raw materials to formulation solutions, enhancing operational stability and risk resilience for Rhine Biotech [10]. Group 4: Market Reaction - Following the announcement of the control change and restructuring plan, Rhine Biotech's stock price hit the daily limit, closing at 9.57 yuan per share, a 10% increase [11].

【深圳商报讯】(记者钟国斌)莱茵生物（002166）12月23日晚公告称，12月22日，公司控股股东、实际 控制人秦本军与广州德福营养签署了《控制权变更框架协议》《股份转让协议》《表决权放弃协议》， 约定秦本军向广州德福营养协议转让其所持上市公司6000万股股份，占公司总股本比例为8.09%；放弃 1.89亿股股份表决权，占公司总股本比例为25.50%；保留2224.83万股股份表决权，占公司总股本比例 为3.00%。本次协议转让完成股份过户且公司董事会完成换届后，广州德福营养将成为公司控股股东。 据莱茵生物披露的《发行股份购买资产并募集配套资金暨关联交易预案》，本次发行股份购买资产的发 行价格选择重组首次董事会决议公告日前20个交易日股票交易均价作为市场参考价，最终确定为6.81 元/股，发行价格不低于市场参考价的80%。 12月24日，莱茵生物复牌一字涨停，截至收盘，该股报9.57元/股。 同日，莱茵生物与德福金康普、厦门德福金普签署了《发行股份购买资产协议》，与广州德福营养签署 了《附条件生效的股份认购协议》，与李洋、宋军签署了《股权转让协议》。协议约定公司向德福金康 普和厦门德福金普发行股份购买其合计 ...

Core Viewpoint - Rhine Biotech (002166) has officially disclosed its asset restructuring and control change plan after a 10-day trading suspension, intending to issue shares to Guangzhou Defu Nutrition Investment Partnership and change its controlling shareholder to Guangzhou Defu Nutrition [1][2] Group 1: Share Transfer and Control Change - The control change framework agreement was signed on December 22, where Qin Benjun, the controlling shareholder, will transfer 8.09% of shares to Guangzhou Defu Nutrition and relinquish 25.50% of voting rights while retaining 3% [2] - After the transaction, Guangzhou Defu Nutrition will hold 8.09% of shares and 11.17% of voting rights, while Qin Benjun will retain 28.50% of shares and 4.14% of voting rights [2] - The total transaction price is estimated at 646 million yuan, with a transfer price of 10.76 yuan per share, representing a premium of 23.68% compared to the closing price of 8.70 yuan before the suspension [2] Group 2: Strategic Intent and Business Expansion - Guangzhou Defu Nutrition, established on December 2, 2025, is an investment company focused on the healthcare sector, managing nearly 24 billion yuan in healthcare assets [3] - Rhine Biotech aims to leverage Defu Capital's resources to enhance its investment and acquisition capabilities in the healthcare sector, creating a comprehensive health ecosystem [3] - The company has signed agreements to acquire 80% of Beijing Jinkangpu, a leading enterprise in the field of nutritional fortifiers, thereby expanding its business into the nutritional fortifier formulation sector [4][6] Group 3: Financial Performance of Beijing Jinkangpu - As of September 2023, Beijing Jinkangpu reported total assets of 593 million yuan and net assets of 535 million yuan, with revenues of 338 million yuan and a net profit of 40.33 million yuan for the first three quarters of 2025 [4]